Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.70 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | RAD52 | P43351 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7330423 | 0.91 | KMT2A (0.67) | APPPDE5AMAPK1RAD52POLB | |
| SCHEMBL8898682 | 0.86 | APP (0.60) | APPPDE5AMAPK1RAD52POLB | |
| SCHEMBL10839105 | 0.84 | APP (0.70) | APPPDE5AMAPK1RAD52HTT | |
| SCHEMBL30125140 | 0.84 | APP (0.70) | APPPDE5AMAPK1RAD52HTT | |
| SCHEMBL4904310 | 0.84 | APP (0.70) | APPPDE5AKDM4ESLC2A1ALDH1A1 | |
| SCHEMBL16404321 | 0.83 | MAPK1 (0.82) | PDE5AMAPK1RAD52POLBTAAR1 | |
| SCHEMBL17799869 | 0.83 | APP (1.00) | APPPDE5AMAPK1HTTKDM4E | |
| SCHEMBL23723296 | 0.82 | APP (0.63) | APPPDE5ARAD52KDM4EALDH1A1 | |
| SCHEMBL15502283 | 0.81 | ACP1 (0.68) | APPPDE5APOLBSMN1; SMN2KDM4E | |
| SCHEMBL30125146 | 0.81 | APP (0.67) | APPPDE5APOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
| CN-110256364-A | A kind of quinazoline compounds and its preparation method and application | 西北农林科技大学 | 2019-09-20 | — | — | CN | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| EP-0491814-B1 | TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS | NOVO NORDISK AS (DK) | 1995-12-06 | — | — | EP | disclosed |
| EP-0491814-A1 | TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | NOVO NORDISK AS (DK) | 1992-07-01 | — | — | EP | disclosed |
| US-5100895-A | Imidazoquinazoline compounds; anticonvulsants, anxiolytics, hypnotics, antipsychotics, antiemetics, improving cognitive function | NOVO NORDISK A/S (DK) | 1992-03-31 | — | — | US | disclosed |
| WO-1991003478-A1 | TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS | NOVO NORDISK A/S (DK) | 1991-03-21 | — | — | WO | disclosed |
| EP-0417027-A1 | Tetracyclic imidazoquinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | NOVO NORDISK A/S (DK) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | APP 4864/4885PDE5A 784/4885MAPK1 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.